ClinicalTrials.gg
CompletedNCT02054481Updated Sep 19, 2016Results posted

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

A Phase 2 interventional study of BI 655066 and BI 655066 in Psoriasis, sponsored by Boehringer Ingelheim. Completed at 32 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-19.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
15th of 30
166 · median 162
Started
2014
with 1 other
Phase 2
4 of 30
none open now
Registered
2nd of 30
by date
Lead sponsor
1 of 30
Boehringer Ingelheim

Among the 30 studies testing risankizumab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 2, and was the 2nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >/= 18.5 and \< 40 kg/m²
  • Patients with stable moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis involving >/= 10% body surface area, with disease severity PASI >/= 12 and sPGA score of moderate and above (score of at least 3) at screening visit and visit 2 (randomisation), as assessed by the investigator
  • Psoriasis disease duration of at least 6 months prior to screening, as assessed by the investigator
  • Patients must be candidates for systemic psoriasis treatment or phototherapy, as assessed by the investigator
  • Patients must be suitable candidates for ustekinumab (Stelara®) therapy as given in the local labelling
  • Patient must give and sign an approved consent form prior to any study procedures in accordance with GCP and local legislation

Exclusion criteria

Exclusion criteria:

  • Patients with guttate, erythrodermic, or pustular psoriasis and patients with drug-induced psoriasis, as diagnosed by the investigator
  • Evidence of current or previous disease, medical condition other than psoriasis, or finding of the medical examination (including vital signs and ), that in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This criterion provides an opportunity for the investigator to exclude patients based on clinical judgment, even if other eligibility criteria are satisfied. (Psoriatic arthritis is not considered an exclusion criterion)
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders, or history of orthostatic hypotension, fainting spells or blackouts, that in the investigator's judgement, could jeopardize the safe conduct of the study.
  • Clinically important acute or chronic infections including hepatitis and .

With regards to tuberculosis the following applies:

Have signs or symptoms suggestive of current active or latent TB upon medical history, physical examination and/or a chest radiograph (both posterior-anterior and lateral views, taken within 3 months prior to the first administration of study drug and read by a qualified radiologist).

Have history of latent or active TB prior to screening, except for patients who have documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent.

Have positive IGRA testing (QuantiFERON-TB Gold) within 2 months prior to or during screening, in which active TB has not been ruled out, except for patients with history of latent TB and documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent.

  • Have had a \</= 12 weeks prior to randomisation (visit 2). Patients must agree not to receive a live vaccination during the study. No BCG vaccines should be given for one year prior to randomisation (visit 2), during the study and for one year after last administration of study drug (according to the Stelara® SPC).
  • History of clinically significant to a systemically administered biologic agent or its
  • History of in the past 5 years or suspicion of active malignant disease except treated cutaneous squamous cell or basal cell carcinoma
  • Has received any therapeutic agent directly targeted to IL-12, IL-23 (including ustekinumab (Stelara®))
  • Use of biologic agents within 12 weeks (infliximab, etanercept, adalimumab, other biologics) prior to treatment, systemic anti-psoriatic medications or phototherapy within 4 weeks prior to treatment, or topical anti-psoriasis medications within 2 weeks prior to treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Arm 1

    BI 655066 s.c.

    Drug: BI 655066

  • Experimental
    Arm 2

    BI 655066 s.c.

    Drug: BI 655066

  • Experimental
    Arm 3

    BI 655066 s.c.

    Drug: BI 655066

  • Active comparator
    Arm 4

    Ustekinumab s.c.

    Drug: Ustekinumab

Interventions

06

What researchers measure

Primary outcomes

  1. Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12

    Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24

    Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Baseline, Week 12 and Week 24

  2. Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12

    Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Baseline and Week 12

  3. Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12

    Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Baseline and Week 12

  4. Achievement of PASI90 at Week 24

    Percentage of participants who achieved PASI90 at Week 24. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Week 24

  5. Percentage Change in PASI Score From Baseline at Week 12

    Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12. PASI score ranges from 0 (best) to 72 (worst).

    Time frame: Baseline and Week 12

  6. Achievement of sPGA Clear or Almost Clear at Week 12

    Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12. sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).

    Time frame: Week 12

  7. Time to Loss of PASI50 Response

    Time to loss of PASI50 response.

    Time frame: From first drug administration until end of follow-up period, up to 48 weeks

07

Results

Posted Sep 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgStelara
Started43414240
Completed39394039
Not completed4221
Withdrew: Adverse event1101
Withdrew: Lost to follow-up1000
Withdrew: Other reason2120

Outcome measures

PrimaryAchievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12

Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 1232.6 (19.1 to 48.5)73.2 (57.1 to 85.8)81.0 (65.9 to 91.4)77.1 (66.6 to 85.6)40.0 (24.9 to 56.7)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (net): 36.4 · 95% CI 19.0 to 53.8Difference calculated as BI 90+180 mg minus Stelara
SecondaryAchievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24

Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Number · Percentage of participants
Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Week 1267.4 (51.5 to 80.9)97.6 (87.1 to 99.9)90.5 (77.4 to 97.3)94.0 (86.5 to 98.0)77.5 (61.5 to 89.2)
Week 2455.8 (39.9 to 70.9)92.7 (80.1 to 98.5)92.9 (80.5 to 98.5)92.8 (84.9 to 97.3)70.0 (53.5 to 83.4)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0355 · Mean difference (net): 14.6 · 95% CI 1.0 to 28.2Difference calculated as BI 90+180 mg minus Stelara
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0062 · Mean difference (net): 21.1 · 95% CI 6.0 to 36.2Difference calculated as BI 90+180 mg minus Stelara
SecondaryAchievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12

Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 1214.0 (5.3 to 27.9)41.5 (26.3 to 57.9)50.0 (34.2 to 65.8)45.8 (34.8 to 57.1)17.5 (7.3 to 32.8)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0008 · Mean difference (net): 27.1 · 95% CI 11.3 to 42.9Difference calculated as BI 90+180 mg minus Stelara
SecondaryAchievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12

Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 1293.0 (80.9 to 98.5)100.0 (91.4 to 100.0)95.2 (83.8 to 99.4)97.6 (91.6 to 99.7)87.5 (73.2 to 95.8)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0706 · Mean difference (net): 10.1 · 95% CI -0.8 to 21.1Difference calculated as BI 90+180 mg minus Stelara
SecondaryAchievement of PASI90 at Week 24

Percentage of participants who achieved PASI90 at Week 24. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Achievement of PASI90 at Week 24
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Achievement of PASI90 at Week 2430.2 (17.2 to 46.1)65.9 (49.4 to 79.9)85.7 (71.5 to 94.6)75.9 (65.3 to 84.6)55.0 (38.5 to 70.7)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0300 · Mean difference (net): 19.8 · 95% CI 1.9 to 37.7Difference calculated as BI 90+180 mg minus Stelara
SecondaryPercentage Change in PASI Score From Baseline at Week 12

Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12. PASI score ranges from 0 (best) to 72 (worst).

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage of PASI score
Percentage Change in PASI Score From Baseline at Week 12
Percentage of PASI scoreBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Percentage Change in PASI Score From Baseline at Week 12-79.7 ± 19.5-93.4 ± 7.7-90.7 ± 23.1-92.1 ± 17.1-82.1 ± 19.5
SecondaryAchievement of sPGA Clear or Almost Clear at Week 12

Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12. sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Achievement of sPGA Clear or Almost Clear at Week 12
Percentage of participantsBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Achievement of sPGA Clear or Almost Clear at Week 1262.8 (46.7 to 77.0)90.2 (76.9 to 97.3)90.5 (77.4 to 97.3)90.4 (81.9 to 95.7)67.5 (50.9 to 81.4)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Cochran-Mantel-Haenszel · p = 0.0072 · Mean difference (net): 21.2 · 95% CI 5.7 to 36.6Difference calculated as BI 90+180 mg minus Stelara
SecondaryTime to Loss of PASI50 Response

Time to loss of PASI50 response.

Time frame:
From first drug administration until end of follow-up period, up to 48 weeks
Reported as:
Median · Days
Time to Loss of PASI50 Response
DaysBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgBI 655066 90+180 mgStelara
Time to Loss of PASI50 Response253 (212 to 285)NA (NA to NA)NA (NA to NA)NA (NA to NA)338 (253 to NA)
Statistical analysis
  • BI 655066 90+180 mg vs Stelara · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.1844 · 95% CI 0.1 to 0.4

Adverse events

Collected over From first drug administration until 15 weeks after the last drug administration, up to 231 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 655066 18 mg—5/43 (11.6%)23/43 (53.5%)
BI 655066 90 mg—6/41 (14.6%)22/41 (53.7%)
BI 655066 180 mg—0/42 (0%)20/42 (47.6%)
Stelara—3/40 (7.5%)17/40 (42.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgStelara
BronchitisInfections and infestations0/430/410/421/40
DiverticulitisInfections and infestations0/430/410/421/40
Urinary tract infectionInfections and infestations0/430/410/421/40
Iron deficiency anaemiaBlood and lymphatic system disorders0/431/410/420/40
Acute myocardial infarctionCardiac disorders0/431/410/420/40
Coronary artery occlusionCardiac disorders0/431/410/420/40
Gastrointestinal haemorrhageGastrointestinal disorders0/431/410/420/40
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/431/410/420/40
Salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/431/410/420/40
Cerebrovascular accidentNervous system disorders0/431/410/420/40
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBI 655066 18 mgBI 655066 90 mgBI 655066 180 mgStelara
NasopharyngitisInfections and infestations15/4314/4111/425/40
HeadacheNervous system disorders5/432/413/424/40
SinusitisInfections and infestations1/430/411/424/40
GastroenteritisInfections and infestations1/434/410/420/40
Back painMusculoskeletal and connective tissue disorders2/434/411/421/40
MyalgiaMusculoskeletal and connective tissue disorders0/431/413/423/40
PsoriasisSkin and subcutaneous tissue disorders3/431/410/423/40
RhinitisInfections and infestations0/433/411/421/40
Upper respiratory tract infectionInfections and infestations0/433/411/421/40
ArthralgiaMusculoskeletal and connective tissue disorders1/432/413/422/40

Baseline characteristics

Safety Set (SAF) which Included all randomised patients who received at least 1 dose of trial medication and was based on the first treatment received.

Age, Continuous
Age, Continuous(Years)BI 655066 18 mgBI 655066 90 mgBI 655066 180 mgStelaraTotal
Mean44.1 ± 14.249.3 ± 13.344.9 ± 14.045.4 ± 12.145.9 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)BI 655066 18 mgBI 655066 90 mgBI 655066 180 mgStelaraTotal
Female2011131357
Male23302927109
08

Study locations

32 sites
  • 1311.2.10010 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1311.2.10013 Boehringer Ingelheim Investigational Site
    Port Orange, Florida, United States
  • 1311.2.10003 Boehringer Ingelheim Investigational Site
    Arlington Hts, Illinois, United States
  • 1311.2.10002 Boehringer Ingelheim Investigational Site
    Bay City, Michigan, United States
  • 1311.2.10004 Boehringer Ingelheim Investigational Site
    Fridley, Minnesota, United States
  • 1311.2.10001 Boehringer Ingelheim Investigational Site
    East Windsor, New Jersey, United States
  • 1311.2.10009 Boehringer Ingelheim Investigational Site
    Verona, New Jersey, United States
  • 1311.2.10007 Boehringer Ingelheim Investigational Site
    Raleigh, North Carolina, United States
  • 1311.2.10005 Boehringer Ingelheim Investigational Site
    Portland, Oregon, United States
  • 1311.2.10006 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 1311.2.10011 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1311.2.10012 Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
  • 1311.2.20002 Boehringer Ingelheim Investigational Site
    Markham, Ontario, Canada
  • 1311.2.20005 Boehringer Ingelheim Investigational Site
    Peterborough, Ontario, Canada
  • 1311.2.20003 Boehringer Ingelheim Investigational Site
    Waterloo, Ontario, Canada
  • 1311.2.20004 Boehringer Ingelheim Investigational Site
    Sainte-Foy, Quebec, Canada
  • 1311.2.35802 Boehringer Ingelheim Investigational Site
    Helsinki, Finland
  • 1311.2.35801 Boehringer Ingelheim Investigational Site
    Turku, Finland
  • 1311.2.33005 Boehringer Ingelheim Investigational Site
    Marseille, France
  • 1311.2.33002 Boehringer Ingelheim Investigational Site
    Nice, France
  • 1311.2.33001 Boehringer Ingelheim Investigational Site
    Paris, France
  • 1311.2.33004 Boehringer Ingelheim Investigational Site
    Pessac, France
  • 1311.2.33003 Boehringer Ingelheim Investigational Site
    Rouen, France
  • 1311.2.33006 Boehringer Ingelheim Investigational Site
    Toulouse, France
  • 1311.2.49001 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1311.2.49003 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 1311.2.49005 Boehringer Ingelheim Investigational Site
    Lübeck, Germany
  • 1311.2.49002 Boehringer Ingelheim Investigational Site
    Mainz, Germany
  • 1311.2.49004 Boehringer Ingelheim Investigational Site
    Münster, Germany
  • 1311.2.47001 Boehringer Ingelheim Investigational Site
    Oslo, Norway
  • 1311.2.47002 Boehringer Ingelheim Investigational Site
    Ålesund, Norway
  • 1311.2.46001 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
09

References and documents

Publications

  • Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020 May;59(5):575-589. doi: 10.1007/s40262-019-00829-2. PubMed 31667790 ↗
  • Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z. PubMed 31054118 ↗
  • Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. PubMed 28423301 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Nov 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2014
First posted
Feb 4, 2014
Start
Feb 2014
Primary completionActual
Nov 2014
CompletionActual
Jul 2015
Results first posted
Sep 19, 2016
Last update
Sep 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02054481
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Feb 2014
Primary completion
Nov 2014
Completion
Jul 2015
Results posted
Sep 19, 2016
Last update
Sep 19, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion